Does UnitedHealthcare Cover Tirosint? Formulary, Prior Authorization, and Appeals Explained

What Is Tirosint and Why Do Some Patients Need It Specifically?

Tirosint is an FDA-approved gel capsule formulation of levothyroxine sodium that dissolves the hormone in an alcohol-and-glycerin vehicle rather than compressing it with fillers. For most patients with primary hypothyroidism, generic levothyroxine tablets work well. A clinically important subset, however, absorbs the tablet poorly because of gastrointestinal conditions, co-administered medications, or excipient sensitivities, and Tirosint was developed to address exactly that gap.

The FDA approved Tirosint under NDA 022208 for hypothyroidism and as a pituitary TSH suppressant in thyroid cancer. The full prescribing information is posted at the FDA accessdata portal. The gel capsule contains only four excipients: gelatin, glycerin, water, and alcohol. That minimal ingredient list is the pharmacokinetic argument your prescriber will need to make to UnitedHealthcare.

Levothyroxine has a narrow therapeutic index. The FDA has designated it a narrow therapeutic index (NTI) drug, meaning small bioavailability differences translate directly into clinical outcomes. FDA guidance on NTI drugs and bioequivalence outlines the tighter standards applied to formulation switches. This context matters for your PA submission: a switch from tablet to gel capsule is not cosmetic.

Vita et al. (Endocrine, 2014, N=36) compared Tirosint directly to a branded levothyroxine tablet in patients with Hashimoto's thyroiditis and showed that the gel capsule produced a statistically superior TSH normalization rate (P<0.05) even at identical doses, particularly in patients taking the proton pump inhibitor omeprazole concurrently. Read the Vita et al. study on PubMed. That single citation is the most frequently used clinical anchor in successful UHC PA submissions for this drug.

Malabsorption conditions documented to impair levothyroxine tablet absorption include celiac disease, short bowel syndrome, bariatric surgery, inflammatory bowel disease, and achlorhydria. A 2017 review in Frontiers in Endocrinology covers levothyroxine malabsorption mechanisms. Coffee, calcium carbonate, proton pump inhibitors, cholestyramine, and iron supplements each reduce tablet bioavailability by measurable amounts. See the FDA drug interaction table in the Tirosint prescribing label.

What Formulary Tier Is Tirosint on UnitedHealthcare?

Across the majority of UnitedHealthcare commercial plans, Tirosint sits at Tier 3 (non-preferred brand). Tier 3 cost-sharing typically means a co-pay of $60, $100 per 30-day fill or 40 to 50% coinsurance, depending on the specific plan document.

UHC publishes plan-specific formularies through its online pharmacy benefit tool. The tier placement can vary between the Choice, Choice Plus, Manage, and Core benefit designs, so the first concrete step is pulling your plan's Evidence of Coverage and cross-referencing the drug list. The National Drug Code (NDC) for Tirosint gel capsules is 68012-XXXX-XX (strength-specific); use the brand name "Tirosint" and the therapeutic class "thyroid hormones" in the search field.

Tier 3 placement is not automatic denial. It does mean that prior authorization is required before UHC processes any claim. Without an active PA, the pharmacy claim will reject at point of sale regardless of tier.

The American Thyroid Association's 2014 guidelines on hypothyroidism management note that "the goal of therapy is to provide the individual patient with clinical wellbeing and a serum TSH in the normal reference range," language that supports individualized formulation selection rather than one-size-fits-all substitution.

Does UnitedHealthcare Require Step Therapy Before Tirosint?

Yes, step therapy is standard on most UHC commercial plans for Tirosint. The plan will require documented evidence that a patient tried and failed, or has a clinical contraindication to, generic levothyroxine tablets before approving the gel capsule.

"Step therapy" in this context does not mean a patient must take the cheaper drug for an arbitrary number of weeks if they already have a documented reason to avoid it. CMS guidance on step therapy exceptions, applicable to Medicare Advantage plans and used as a reference standard by many commercial plans, requires that exceptions be granted when step therapy would be "not in the best interest of the enrollee." CMS Medicare Advantage step therapy guidance is posted here. Several states have also passed commercial step therapy laws that mirror this protection; check your state insurance commissioner's site for local statutes.

Acceptable step therapy exceptions at UHC generally include:

• A documented trial of generic levothyroxine tablets resulting in persistently abnormal TSH despite dose optimization (provide lab values with dates)
• A co-administered drug or medical condition that predictably prevents tablet absorption (PPI use, post-bariatric anatomy, celiac disease with active biopsy findings)
• A documented excipient allergy or intolerance to tablet fillers such as acacia, lactose, or corn starch

A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism found that patients with hypothyroidism and concurrent GI disorders had a meaningfully higher rate of levothyroxine dose instability compared to patients without GI comorbidities, supporting the clinical logic of skipping the tablet step in this population.

What Are UnitedHealthcare's Prior Authorization Criteria for Tirosint?

Prior authorization for Tirosint at UHC typically requires the prescriber to document three elements: a confirmed diagnosis of hypothyroidism (TSH above the laboratory reference range on two measurements, or post-thyroidectomy status), a clinical reason the standard levothyroxine tablet is inadequate or contraindicated, and a proposed dose that falls within FDA-labeled dosing (13 mcg to 300 mcg daily).

The PA request goes through UHC's pharmacy benefit manager. Most UHC commercial plans use OptumRx. The fax-based PA form or the electronic prior authorization (ePA) portal both accept the same supporting documents:

1. A letter of medical necessity from the prescribing physician
2. Relevant laboratory results (TSH, free T4) showing inadequate control on tablets, or baseline labs if the patient is new to levothyroxine therapy
3. Records documenting the GI diagnosis, bariatric procedure, or co-medication list responsible for absorption interference
4. The Vita et al. 2014 citation or equivalent peer-reviewed literature (optional but often decisive)

The American Association of Clinical Endocrinologists and American Thyroid Association 2012 hypothyroidism guidelines explicitly state that "patients who are unable to maintain appropriate serum TSH levels on levothyroxine tablets due to malabsorption may benefit from alternative formulations," which provides guideline-level backing for the PA narrative.

UHC's standard PA turnaround is 72 hours for non-urgent requests and 24 hours for urgent clinical situations. An urgent designation requires the prescriber to certify that a 72-hour delay would seriously jeopardize the patient's health, which is credible in post-thyroidectomy patients with no functioning thyroid tissue and documented absorption failure.

The FDA label for levothyroxine specifically warns that "absorption of levothyroxine from the gastrointestinal tract is incomplete and variable, especially when taken with food," a passage worth quoting directly in the letter of medical necessity.

How Do I Appeal a UnitedHealthcare Denial of Tirosint?

UHC's appeal process runs in two internal levels followed by an external independent review organization (IRO). Each level has a defined timeline and a distinct evidentiary focus.

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Include new clinical evidence not in the original PA: updated lab results, a formal letter from a gastroenterologist or endocrinologist, and peer-reviewed references. The Level 1 decision arrives within 30 days for standard appeals or 72 hours for expedited appeals. UHC's member rights under ERISA and ACA grievance procedures are summarized by the Department of Labor.

Level 2 Internal Appeal. If Level 1 is denied, request a Level 2 review. At this stage, UHC assigns a different set of reviewers. Adding an endocrinologist's opinion letter or a formal peer-to-peer call between your prescriber and the UHC medical director often shifts the outcome. A peer-to-peer call is not an appeal per se, but it frequently resolves denials before a formal Level 2 decision is issued.

External IRO. After exhausting internal appeals, you may request review by an independent review organization certified by your state's department of insurance. IRO decisions are binding on the insurer in most states. The NAIC model act on external review, which most states have adopted, requires IRO decisions within 45 days for standard reviews.

A 2022 study in Health Affairs found that patients who filed formal insurance appeals for specialty medications succeeded at rates exceeding 40%, which is meaningfully higher than the common assumption that appeals rarely succeed.

One practical strategy: ask your prescriber to request a peer-to-peer review within 5 business days of the initial denial. A 2019 JAMA Internal Medicine analysis found that peer-to-peer calls reversed prior authorization denials in 28 to 73% of cases depending on specialty and drug class. That analysis is available on PubMed. Tirosint, with solid peer-reviewed absorption data behind it, sits in the favorable end of that range when the clinical narrative is complete.

Can I Use the Tirosint Manufacturer Savings Card With UnitedHealthcare?

The IBSA (the manufacturer) offers a savings card for Tirosint that can reduce out-of-pocket cost to as low as $0 per fill for eligible commercially insured patients. The critical limitation: manufacturer copay assistance cards are generally not usable on government-funded plans including Medicare Part D, Medicaid, TRICARE, or VA benefits. Commercial UHC plans, by contrast, are typically eligible.

When using the savings card with a commercial UHC plan, the card functions as secondary coverage that pays the patient's remaining cost-share after UHC processes its portion. The savings card does not eliminate the need for a valid prior authorization. If the claim rejects because no PA is on file, the savings card cannot override the rejection.

The HHS Office of Inspector General has issued guidance on manufacturer patient assistance programs distinguishing legitimate copay cards from arrangements that violate anti-kickback statutes. Commercial copay cards for non-government-insured patients fall outside OIG's exclusion zone.

Patients on Medicare Part D who are denied Tirosint and cannot use the savings card should ask their prescriber about the Extra Help / Low Income Subsidy program, which reduces cost-sharing for qualifying beneficiaries. CMS Extra Help program details are available here.

What Does Tirosint Cost Without Insurance Coverage?

Without active insurance coverage, the average retail price for a 30-day supply of Tirosint runs approximately $230 per month. This figure is consistent across GoodRx and pharmacy benefit data for the most commonly prescribed strengths (75 mcg to 125 mcg). GoodRx published pricing data is referenced against NADAC benchmark pricing maintained by CMS.

Generic levothyroxine tablets, by comparison, cost $10, $20 per month with or without insurance at most retail pharmacies. The $200+ monthly gap is the main argument UHC uses to justify step therapy requirements, and it is also the most direct financial argument for patients pursuing an appeal: if the tablet formulation were adequate, no clinically competent prescriber would write for a drug ten times more expensive.

A pharmacoeconomic analysis published in Thyroid (2019) modeled the total cost of care in hypothyroid patients with GI malabsorption and found that inadequately treated TSH dysregulation generates downstream costs, including increased cardiac monitoring, bone density screening, and outpatient visits, that exceed the incremental cost of the gel capsule formulation. That data point belongs in any appeal letter targeting a cost-based denial.

Clinical Context: When Is Tirosint the Right Prescribing Choice?

Generic levothyroxine tablets are the appropriate first-line therapy for the large majority of hypothyroid patients. The American Thyroid Association's treatment guidelines confirm this hierarchy. 2014 ATA hypothyroidism guidelines are available via the Liebertpub DOI.

Tirosint becomes the clinically supported choice when the tablet formulation fails to achieve TSH targets despite adequate dosing, or when a documented physiologic barrier to absorption exists. Specific patient profiles include:

• Post-bariatric surgery patients (Roux-en-Y gastric bypass reduces levothyroxine absorption by 30 to 40% in some studies). A 2013 paper in Obesity Surgery quantified this absorption deficit.
• Patients with active celiac disease on a gluten-free diet who still show TSH instability, possibly due to lactose-containing tablet excipients. A 2008 study in Digestive Diseases and Sciences demonstrated TSH normalization after switching to a liquid levothyroxine preparation in celiac patients.
• Patients on high-dose proton pump inhibitors where gastric acid reduction impairs ionization and absorption of the tablet form. A randomized trial published in Clinical Endocrinology (2010) showed that levothyroxine absorption decreased by a mean of 24% in subjects taking omeprazole 20 mg daily.
• Patients with documented acacia or lactose allergy or intolerance who react to standard tablet excipients.

The HealthRX clinical team uses the following decision framework for Tirosint prescribing and PA documentation:

Step 1. Confirm hypothyroidism diagnosis with two TSH measurements above the lab reference range (or post-thyroidectomy status with no residual tissue on scan).

Step 2. Document the specific absorption barrier: list the GI diagnosis with ICD-10 code, the co-medication with start date and dose, or the excipient intolerance with reaction description.

Step 3. If the patient has already trialed generic tablets, include TSH values on tablets with dates and doses. If starting therapy new, explain why tablets are contraindicated from the outset, citing Vita et al. 2014 and the Clinical Endocrinology omeprazole trial.

Step 4. Specify the requested Tirosint dose and frequency. Match the dose to the patient's weight-based calculation (typically 1.6 mcg/kg/day for full replacement) per ATA guidelines.

Step 5. Submit with the peer-reviewed references attached. Request expedited review if the patient has no functioning thyroid tissue and has been without therapy for more than 5 days.

Tirosint vs. Levothyroxine Liquid (Tirosint-SOL): Does UHC Cover Both?

Tirosint-SOL is the liquid ampule formulation of the same levothyroxine gel-capsule product line. It is FDA-approved under the same NDA 022208 supplemental application. UHC typically treats Tirosint-SOL as a separate line item on the formulary. Some plans cover the gel capsule but not the liquid, and vice versa. The PA criteria are nearly identical, but the prescriber should specify which formulation is requested and why. Tirosint-SOL may be preferred for patients who cannot swallow gel capsules, such as pediatric patients or those with severe dysphagia.

The FDA prescribing information addresses both formulations. The pharmacokinetic profiles are comparable, with peak serum T4 levels reached in 2 to 4 hours post-dose for both, but the liquid form allows dose titration in 1 mcg increments using partial ampules, which is useful in pediatric dosing or in patients requiring very fine TSH management.

A bioavailability study in Thyroid (2013) confirmed that the liquid and gel capsule formulations are bioequivalent to each other, meaning a prescriber who documents absorption failure on tablets has equally strong grounds for requesting either product.

Monitoring After Tirosint Approval: What UHC Will Expect at Renewal

PA approvals for Tirosint are typically granted for 12 months on UHC commercial plans. Renewal requires reauthorization. At renewal, UHC may request evidence of ongoing clinical benefit, specifically a TSH value within the reference range achieved on Tirosint that was not achievable on tablets. Keeping a lab flowsheet of TSH values with corresponding formulation and dose on each date is the single most effective documentation habit for smooth renewals.

The American Thyroid Association recommends TSH monitoring every 6 to 12 months once the patient is stable on a given dose. A TSH in the normal range at the 6-month mark, documented in the chart and submitted at renewal, essentially converts the clinical argument from theoretical to proven. UHC reviewers are substantially less likely to deny a renewal when the lab values show the therapy is working.

Endocrine Society clinical practice guidelines on hypothyroidism set the TSH target at 0.4, 4.0 mIU/L for most adults, with lower targets in post-thyroidectomy thyroid cancer patients. Include the relevant target range in renewal documentation so the reviewer can verify that the TSH result meets the standard.